Track topics on Twitter Track topics that are important to you
NEW YORK, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its third fiscal quarter ended June 30, 2015.
"The clinical programs for our lead candidate OHR-102 continue to yield positive visual acuity data and there is now a growing body of evidence demonstrating that OHR-102 has the potential to be an important treatment option for patients with various back of the eye diseases," said Jason S. Slakter, MD, newly appointed Chief Executive Officer of Ohr Pharmaceutical. "During the quarter, we were pleased to report additional results from the Phase II IMPACT trial at the ARVO and ASRS meetings, including new data demonstrating visual acuity benefits in patients with classic CNV containing lesions as well as lesions with an occult CNV area less than 10mm2. In addition, data from an investigator sponsored study showed that OHR-102 combination therapy enhanced visual acuity gains in patients with retinal vein occlusion."
"The data we have collected are helping shape the design of a Phase 3 clinical program with OHR-102 in an optimized wet AMD population, which we expect to commence in the second half of calendar 2015," added Dr. Slakter.
Corporate Highlights for the Quarter Ended June 30, 2015, and Recent Events
Financial Results for the Third Quarter Ended June 30, 2015
For the three month period ended June 30, 2015,
Financial Results for the Nine-Month Period Ended June 30, 2015
For the nine month period ended June 30, 2015,
|Conference Call & Webcast|
|Thursday, August 6, 2015 at 5:00pm Eastern Time/2:00pm Pacific Time|
|Replays – Available through August 20, 2015|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. is an ophthalmology research and development company whose lead product, Squalamine, is being studied as an eye drop formulation (OHR-102) in several company-sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases. These diseases include wet-AMD, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition.
Lucentis® is a registered trademark of Genentech, Inc.
CONTACT: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 firstname.lastname@example.org LifeSci Advisors, LLC Michael Wood 646-597-6983 email@example.comNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...